The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
-
Int. J. Tuberc. Lung Dis. · Dec 2014
Randomized Controlled Trial Multicenter Study Pragmatic Clinical TrialCost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
To estimate the incremental cost-effectiveness of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) among human immunodeficiency virus (HIV) infected adults in Rio de Janeiro, Brazil. ⋯ Training health care workers to screen HIV-infected adults with TST and provide IPT to those with latent tuberculous infection can be considered cost-effective relative to the Brazilian GDP per capita.
-
Int. J. Tuberc. Lung Dis. · Mar 2013
Randomized Controlled Trial Comparative StudyRifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
To compare the tolerance, adherence and effectiveness of two approaches for the treatment of latent tuberculosis infection (LTBI): 6 months of isoniazid (6H) vs. 3 months of isoniazid plus rifampicin (3RH). ⋯ The 3RH regimen facilitates adherence to LTBI treatment and offers a safe, well-tolerated and effective alternative.
-
Int. J. Tuberc. Lung Dis. · Jan 2013
Randomized Controlled Trial Multicenter Study Comparative StudySafety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules.
Two paediatric hospitals in Cape Town, South Africa. ⋯ This study suggests that long-term IPT has a low toxicity risk in HIV-infected children. In the absence of chronic viral hepatitis, IPT can be safely re-introduced following recovery from liver injury.
-
Int. J. Tuberc. Lung Dis. · Jul 2011
Randomized Controlled TrialEarly bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.
Delamanid (OPC-67683) is a novel mycolic acid biosynthesis inhibitor active against Mycobacterium tuberculosis at a low minimum inhibitory concentration. ⋯ Delamanid at all dosages was safe, well tolerated and demonstrated significant exposure-dependent EBA over 14 days, supporting further investigation of its pharmacokinetics and anti-tuberculosis activity.
-
Int. J. Tuberc. Lung Dis. · Jun 2011
Randomized Controlled TrialRisk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases.
To compare the risk to household contacts of isoniazid (INH) susceptible and INH-resistant cases of tuberculosis (TB) in a rural community in South India. ⋯ The baseline prevalence of tuberculous infection was substantially higher in contacts of INH-resistant than INH-susceptible patients, but the incidence of tuberculous disease over a 15-year follow-up was similar in the two series, and twice as high as in non-contacts.